MBT-DC

The MBT-DC vaccine is an autologous cellular immunotherapy developed by the Russian biotechnology company Molecular Biology and Technology (MBT). This personalized cancer vaccine is produced by isolating a patient's peripheral blood mononuclear cells (PBMCs), which are then differentiated into dendritic cells (DCs) ex vivo. These dendritic cells are matured and pulsed with either autologous tumor lysates or specific tumor-associated antigens (TAAs) to enable them to present tumor-specific peptides via MHC molecules. Upon re-administration to the patient, typically through intradermal injection, these activated dendritic cells migrate to the lymph nodes where they prime and activate T-cells, inducing a robust cytotoxic T-lymphocyte (CTL) response against the tumor. The vaccine has been investigated in Phase 2 clinical trials for several solid tumors, including glioblastoma multiforme, malignant melanoma, renal cell carcinoma, and colorectal cancer, primarily within the Russian Federation.

Other names

MBT dendritic cell vaccineMolecular Biology and Technology dendritic cell vaccineDendritic cell vaccine (Molecular Biology and Technology)